Company Product Description Indication Status
Phase I
Atossa Therapeutics Inc., of Seattle AT-301 COVID-19 spike glycoprotein inhibitor COVID-19 Final results from study testing drug administered as nasal spray showed safety and tolerability in healthy subjects at 2 dose levels over 14 days
Inhibrx Inc., of San Diego INBRX-105 Designed to agonize 4-1BB selectively in presence of PD-L1 Locally advanced or metastatic solid tumors Data from dose-escalating study showed 8 of 18 evaluable patients (44%) receiving dose levels equal to or greater than 0.1 mg/kg achieved stable disease, with the greatest reduction in tumor volume observed to be 20% by RECISTv1.1; longest duration on treatment was 41 weeks; 7 patients with stable disease tested positive for PD-L1 expression, with a minimum of 1% positivity as determined by immunohistochemistry 
Noxxon Pharma NV, of Berlin NOX-A12 CXCL12 inhibitor  Brain cancer Data safety monitoring board analyzed safety data from initial 4 weeks of treatment of first patient enrolled in third and final dose cohort testing combination with radiotherapy, concluding it is safe to continue recruitment according to study protocol
Sanofi SA, of Paris, and Translate Bio Inc., of Lexington, Mass. MRT-5500 mRNA vaccine COVID-19 Started a phase I/II trial
Phase II
Apeiron Biologics AG, of Vienna APN-01 (alunacedase alfa) Soluble recombinant human ACE2 COVID-19 Results showed fewer patients treated with APN-01 (n=9) died or received invasive ventilation compared to placebo (n=12), although statistical significance was not achieved due to the low total number of events; statistically significant improvement in mechanical ventilator-free days in alive patients and reduction in viral load in the group treated with APN-01 vs. placebo; data also showed positive impact on key biomarkers of the renin angiotensin system, demonstrating in vivo efficacy 
Bergenbio ASA, of Bergen, Norway Bemcentinib AXL inhibitor Refractory non-small-cell lung cancer Completed enrollment in cohort C1 testing combination with Keytruda (pembrolizumab, Merck & Co. Inc.); data expected within 24 weeks
Boehringer Ingelheim GmbH, of Ingelheim, Germany BI-764198 TRP cation channel C6 inhibitor Acute respiratory distress syndrome in patients hospitalized for COVID-19 Decided to discontinue study testing drug in patients requiring non-invasive oxygen support based on recommendation of independent data monitoring committee after interim look at unblinded safety and efficacy data showed clear lack of benefit for use in those patients
Novavax Inc., of Gaithersburg, Md. NVX-CoV2373 COVID-19 spike glycoprotein modulator COVID-19 Complete analysis of phase IIb trial in South Africa showed efficacy of 55.4% among the HIV- negative trial participants in a region where the vast majority of strains are B1.351 escape variants; demonstrated 100% protection against severe disease, including all hospitalization and death
Phase III
Harbour Biomed Holdings Ltd., of Suzhou, China Tanfanercept (HBM-9036)  TNF receptor-1 fragment-based drug Moderate to severe dry eye disease Dosed first patient in China trial
Novavax Inc., of Gaithersburg, Md. NVX-CoV2373 COVID-19 spike glycoprotein modulator COVID-19 Vaccine showed final efficacy of 96.4% against mild, moderate and severe disease caused by original COVID-19 strain U.K. trial; demonstrated 100% protection against severe disease, including all hospitalization and death
Swedish Orphan Biovitrum AB, of Stockholm Avatrombopag Thrombopoietin receptor agonist Immune thrombocytopenia Dosed first patient in pediatric trial

Notes

For more information about individual companies and/or products, see Cortellis.